Introduction
Metabolomics is the all-encompassing term used to describe the study of biological processes pertaining to cell, tissue, or organism metabolic systems. Metabolomics can subsequently be divided into subsets of molecular “omics” study; such as amino acids, sugars, nucleic acids, and lipids.
Lipidomics is a relatively recent research field that has been driven by advances in mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, fluorescence spectroscopy, dual polarisation interferometry and computational methods. Lipids have been consistently recognised as having a key role in many metabolic diseases such as obesity, stroke, hypertension and diabetes. Lipidomics research involves the identification and quantification of the thousands of cellular lipid molecular species as well as their resulting interactions. Investigators in lipidomics examine their structures, functions, interactions, and dynamics; including the changes that occur during perturbation of the system. [2,3]
Hepatic steatosis, or more commonly known as Fatty Liver Disease (FLD) is a condition where excess fat builds up in the liver. While small amounts of fat in the liver is normal, fatty liver disease is diagnosed when fat makes up more than 5–10% of the liver’s weight. It is one of the most common liver disorders worldwide and is closely linked to modern lifestyle factors. Early-stage fatty liver is often reversible through lifestyle changes such as weight loss, improved diet, increased physical activity, and reduced alcohol intake. Often there are little to no symptoms, however FLD can lead to more serious complications such as hepatic fibrosis, cirrhosis and liver cancer.
Influence of obesity and insulin resistance with hepatic steatosis on the human plasma lipidome
The researchers aimed to determine how obesity, insulin resistance, and FLD influence the plasma lipidome. They wanted to identify specific lipid alterations that might be biomarkers or contributors to metabolic abnormalities associated with fatty liver disease.
Participants were stratified into three well-defined groups:
-
Insulin-sensitive lean (ISL)
-
Insulin-sensitive obese (ISO)
-
Insulin-resistant obese with hepatic steatosis (IROS) [1]
Insulin sensitivity was rigorously measured using the hyperinsulinemic–euglycemic clamp, while intrahepatic triglyceride content was quantified by MRI. Using ultra-high performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS), the researchers quantified:
-
759 complex lipid species across 16 lipid subclasses
-
84 eicosanoid metabolites in fasting plasma samples
This design enabled the investigators to distinguish lipidomic effects attributable to adiposity itself from those linked to insulin resistance and hepatic fat accumulation. [4]
Insulin Resistance Drives Major Changes in the Plasma Lipidome
The results demonstrate a striking pattern: obesity alone had little effect on the plasma complex lipidome. Despite substantial differences in body mass index and body fat percentage, individuals with insulin-sensitive obesity had lipid profiles that closely resembled those of lean individuals. [1]
Only a handful of lipid species differed between these two metabolically healthy groups. In contrast, numerous lipid species differed between insulin-sensitive obese individuals and those with insulin resistance and hepatic steatosis, indicating that metabolic impairment rather than fat mass itself alters circulating lipid composition. [1]
Principal component analysis reinforced this conclusion. Lipidomic profiles of individuals with insulin-resistant steatosis formed a distinct cluster, whereas the profiles of lean participants and metabolically healthy individuals with obesity overlapped extensively. This observation suggests that metabolic health status may be a stronger determinant of plasma lipid composition than body weight alone. [5]
Elevated Diacylglycerols Link Hepatic Steatosis to Insulin Resistance
Among the most notable lipidomic alterations in insulin-resistant individuals with hepatic steatosis was the increase in triglycerides and diacylglycerols (DAGs) in plasma. [1] These lipid intermediates are strongly implicated in metabolic disease because they can interfere with insulin signalling pathways.
The study found that circulating DAG levels correlated directly with intrahepatic triglyceride content, indicating that plasma DAGs may reflect lipid accumulation within the liver.
Mechanistically, increased hepatic DAG levels are known to activate protein kinase C-ε, which inhibits insulin receptor signalling and contributes to hepatic insulin resistance. The presence of elevated DAGs in plasma therefore likely reflects increased hepatic lipid production and export, linking liver metabolism to systemic insulin resistance. [4,6]
Phospholipids Associated With Improved Insulin Sensitivity
In contrast to DAGs, several classes of phospholipids were positively associated with insulin sensitivity. Lysophosphatidylcholines (LPC), ether phosphatidylcholines, and lysophosphatidylethanolamines were more abundant in individuals with better insulin responsiveness. [1]
These lipids are often associated with high-density lipoprotein (HDL) particles, which play important roles in lipid transport and metabolic regulation. The relationship between phospholipids and insulin sensitivity may therefore reflect differences in lipoprotein metabolism or antioxidant properties of certain ether lipids.
Importantly, more than one hundred lipid species showed statistically significant correlations with insulin sensitivity, while only a small fraction correlated with body mass index. [1]
This finding further supports the idea that metabolic dysfunction—not adiposity itself—drives widespread changes in the plasma lipidome. [5]
A Three-Lipid Biomarker Panel for Hepatic Steatosis
The study also evaluated whether specific plasma lipids could serve as biomarkers for fatty liver disease. A previously proposed panel consisting of ceramide d42:0, phosphatidylethanolamine 36:1, and phosphatidylinositol 32:1 successfully distinguished individuals with insulin-resistant hepatic steatosis from metabolically healthy participants. [1,7]
This lipid signature achieved an area under the receiver operating characteristic curve of approximately 0.93, indicating strong diagnostic potential.
Such findings suggest that plasma lipidomic profiling may eventually provide a non-invasive method for detecting hepatic steatosis, reducing reliance on imaging or liver biopsy.
Eicosanoids Reflect Adiposity Rather Than Insulin Resistance
Interestingly, not all lipid classes behaved the same way. While complex lipids were strongly linked to insulin resistance, plasma eicosanoids—bioactive lipid mediators derived from polyunsaturated fatty acids—were primarily associated with obesity itself.
Participants with obesity, regardless of insulin sensitivity, exhibited higher levels of several eicosanoids compared with lean individuals. However, there were no significant differences between insulin-sensitive and insulin-resistant individuals with obesity, suggesting that adipose tissue expansion rather than metabolic dysfunction drives these signalling molecules. [1]
This distinction highlights the existence of two partially independent lipidomic pathways in metabolic disease: one linked to adiposity and inflammatory signalling, and another linked to insulin resistance and hepatic lipid metabolism.
Implications for Metabolic Disease and Precision Medicine
These findings have important implications for understanding the biology of obesity-related metabolic disorders. Traditional clinical lipid panels focus primarily on triglycerides and cholesterol, but they capture only a small portion of the vast diversity of lipid species circulating in human plasma.
Comprehensive lipidomic analysis reveals that specific lipid intermediates—particularly diacylglycerols and ceramides—may serve as mechanistic links between hepatic steatosis and insulin resistance. At the same time, other lipid classes appear to reflect inflammatory or adiposity-related pathways. [1]
From a clinical perspective, plasma lipidomics could eventually enable:
-
earlier detection of metabolic dysfunction
-
improved stratification of patients with obesity
-
identification of novel therapeutic targets in lipid metabolism
Conclusion
This study provides compelling evidence that insulin resistance and hepatic steatosis, rather than obesity alone, drive major alterations in the human plasma lipidome. Complex lipid species such as diacylglycerols and triglycerides increase in association with liver fat accumulation, whereas phospholipid subclasses correlate with improved insulin sensitivity. In contrast, eicosanoid signaling molecules appear to reflect adiposity itself.
Together, these findings underscore the power of lipidomics to expand our understanding of metabolic disease beyond traditional lipid measurements, offering new opportunities for biomarker discovery and precision medicine in obesity-related disorders.
Cambridge Isotope Laboratories Reagents Enable High-Precision Lipidomic Profiling in Metabolic Disease Research
The comprehensive lipidomic analysis presented in this study was supported by the use of stable isotope–labelled standards supplied by Cambridge Isotope Laboratories, which played a critical role in ensuring accurate quantification of plasma lipid species. In the lipidomics workflow, the investigators used [U-13C]glucose tracer from Cambridge Isotope Laboratories during the hyperinsulinemic–euglycemic clamp procedure to quantify glucose kinetics and assess whole-body insulin sensitivity.
In addition, the study incorporated stable isotope tracers for metabolic flux measurements, allowing the researchers to precisely track glucose metabolism and link insulin resistance with alterations in the circulating lipidome. These isotopically labelled compounds enabled high-resolution metabolic measurements that complemented the mass-spectrometry-based lipidomic profiling performed in the study.
By integrating Cambridge Isotope Laboratories’ stable isotope tracers with advanced UPLC–MS/MS lipidomics, the researchers were able to generate a detailed map of the human plasma lipidome across different metabolic phenotypes. This approach helped reveal that insulin resistance and hepatic steatosis—rather than obesity alone—drive major alterations in complex plasma lipids, while adiposity primarily influences circulating eicosanoids.
References
Primary Article (Main Source)
Key Supporting References Cited in the Paper
[2] Quehenberger, O., & Dennis, E. A. (2011). The human plasma lipidome. New England Journal of Medicine, 365, 1812–1823.